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Neurologic manifestations and sleep issues 
in osteogenesis imperfecta
Romana Gjergja Juraški1,2, Mirjana Turkalj1,2, Ivan Mikula3, Dragan Primorac1,2,3,4,5,6,7
Osteogenesis imperfecta (OI) is a rare genetic disorder leading to skeletal fragility, fractures and deformities. The main pathophysio-
logic eff ect of OI is reduction in either the quality or the quantity of type I collagen, aff ecting the structures that normally contain type 
I collagen. COL1A1 and COL1A2 genes account for 80% of cases. Our aim was to review relevant information on the neurodevelop-
ment, sleep issues and neurologic complications in OI. The nervous system is involved in OI because of softening of bone at the base 
of the skull, resulting in upwards migration of the upper cervical spine and odontoid process. The disease may directly involve neuro-
vascular structures, leading to cavernous fi stulas, dissections, or aneurysms. The brain parenchyma can be aff ected in OI, with 
 manifestations such as cerebral atrophy, hydrocephalus and cerebellar hypoplasia. Basilar impression/invagination are serious 
 craniocervical junction abnormalities that can be life threatening. There is still no knowledge about sleep phenotype in OI. Neuro-
logic manifestations and sleep disorders are valuable prognostic factors and are highly important features within the phenotypic 
complexity of OI. The measures of prevention in OI stress the need of regular monitoring of these issues from an early age and educa-
tion of both OI patients and their families.
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INTRODUCTION
Osteogenesis imperfecta (OI) is a rare genetic disorder lead-
ing to skeletal fragility, fractures and deformities. The main 
pathophysiologic eff ect of OI is reduction in either the qual-
ity or the quantity of type I collagen, and it is categorized as 
a connective-tissue disease, aff ecting the bones, joints, ears, 
eyes, skin, and other structures that normally contain type I 
collagen. 
At least seventeen distinct types of OI have been described 
on the basis of specifi c genetic mutations so far (1, 2). 
COL1A1 and COL1A2 genes account for 80% of cases of au-
tosomal dominant OI (3, 4), while in other types, mainly au-
tosomal recessive OI mutations in other genes have been 
found, aff ecting bone modeling and resorption (5). 
Occurrences of OI can be classifi ed into groups or types 
based on the clinical and radiologic fi ndings. According to 
the traditional Sillence classifi cation system from 1979 (6), 
type I OI (the most common type) is mild and without sig-
nifi cant bone deformation, type II OI is fatal perinatal form, 
type III is seriously deforming, while type IV OI is less diffi  cult 
deforming. Accurate clinical classifi cation can be diffi  cult be-
cause the characteristics of types I and IV and those of types 
II and III are overlapping. In patients with type I, fractures are 
less common after puberty when ossifi cation is complete 
and the bones are stronger. The average life expectancy of 
this type is slightly reduced because of the risks of fatal bone 
fractures and complications such as basilar invagination. 
In utero fractures of the skull, vertebrae and long bones are 
the main features of type II OI. Other signs of type II include 
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minimal vertebral ossifi cation, beaded ribs, and abnormally 
small chest. Unfortunately, children with type II OI die with-
in the fi rst year of life because of respiratory failure due to 
pulmonary hypoplasia or fatal cerebral hemorrhage (7). 
Type III is the most severe type of OI seen in children that 
survive the neonatal period. Patients with type III can have 
blue sclera, small nose with micrognatism, and soft calvaria. 
Type III tends to progress over time if left untreated. The av-
erage life expectancy for patients with type III OI is slightly 
lower than that for the general population (8). 
The symptoms of type IV may vary in severity from mild 
(similar to type I) to severe (resembling type III). The sclera 
appears normal. The average life expectancy for patients 
with type IV OI might be slightly lower than that for the gen-
eral population (8). Patients with OI experience hypotonia, 
ligament laxity, joint hyperfl exibility and dental abnormali-
ties (dentinogenesis imperfecta), depending on the type 
(Table 1). The Sillence clinical classifi cation has been updat-
ed with new noncollagen mutations in OI and diff erential 
clinical fi ndings (types V-XVI) (9, 10). Using next generation 
sequencing mutations in other genes implicated in variable 
OI phenotype has been introduced (11).
The recent changes in classifi cation have been made in or-
der to reduce it to fi ve subtypes of OI based on phenotype 
only (without signifi cant bone deformation, perinatal lethal, 
progressively deforming, common variable OI with normal 
sclera, and OI with calcifi cation of interosseous membranes) 
(10, 11).
NEURODEVELOPMENTAL ISSUES IN CHILDREN 
WITH OSTEOGENESIS IMPERFECTA
Children with OI often demonstrate delays in meeting some 
developmental milestones, but this can improve with age. 
A delay in adoption of upright position has been docu-
mented in children with OI. This delay is most evident in the 
severe types of OI. The mean age at which standing occurs 
has been reported to be 11 months in type I, 16 months in 
type IV, and 40 months in type III OI (12, 13).
Neurodevelopmental delays can be the result of repeated 
immobilizations after fractures, misalignment of the long 
bones and joints, and general hypotonia and ligament laxi-
ty that are common in OI (14). 
The reduced mobility and early wheelchair dependence are 
serious eff ects of severe types of OI. Immobilization of the 
musculoskeletal system is typically followed by loss of mus-
cle mass and progressive loss of bone mass (15). A primary 
bone disease such as OI leads to secondary osteopenia due 
to fractures and immobilization (16). Hip and back pain due 
to poor alignment and leg length discrepancies occur in all 
types of OI and pain is an important negative factor in fur-
ther psychomotor development in children with OI. One 
long-term follow-up study provided information concern-
ing the natural course of developmental outcome parame-
ters of OI in childhood, and showed that joint range of mo-
tion and muscle strength did not change signifi cantly over 
time, even though the functional ability improved over 
time, but especially in types III and IV, it still did not reach 
normative values, possibly because of a plateau phase in 
functional ability (17).
Muscle mass is decreased in OI, even when short stature is 
taken into account. Dynamic muscle tests aiming at maxi-
mal excentric force production reveal functional defi cits 
that cannot be explained by low muscle mass alone (18). At 
present, the determinants of muscle mass and function in 
OI have not yet been clearly defi ned (18).
Severe muscle weakness can be the fi rst sign of OI in an 
early age, presented as metabolic myopathy (19).
Lee et al. describe atypical presentation of a girl with features 
of OI and Russell Silver syndrome with severe hypotonia 
and postnatal growth impairment and microcephalia, car-
rying a missense mutation in COL1A1 gene (20). Reports like 
this one support the expanded phenotypic spectrum of 
type I collagenopathy and the awareness of neurodevelop-
mental issues in OI. 
Mild to signifi cant short stature and slow growth rate occur 
in OI. Height and weight charts for the child with OI are 
available (21). The increase in head circumference is most 
notable between the ages of 2 and 3 years. In a cross-sec-
tional study of 343 patients with diff erent types of OI con-
ducted by Germain-Lee et al., the linear growth patterns, in 
addition to the marked increase in weight over time, indi-
cated a need for early lifestyle modifi cations in children with 
OI, especially the need for weight control (22).
Progressive hearing loss is an important feature of the disease 
that can have negative eff ect on neurodevelopment, espe-
cially if it is present from an early age. In 7% of children with 
OI, hearing loss was evident at the age between 5 and 9 
years, at fi rst conductive then perceptive hearing loss (23). It 
seems that bisphosphonate therapy does not infl uence hear-
ing loss. The authors recommended that audiometry be per-
formed in children with OI even without symptoms of hear-
ing loss at the age of 10 years, and repeated every 3 years (23). 
The incidence of autism, hyperactivity and epilepsy is be-
lieved to be similar to that in the general population (24, 25), 
although it was suggested that electroencephalography 
(EEG) abnormalities (prominent photic driving responses, fo-
cal fi ndings over the right hemisphere, of paroxysmal nature) 
occured more frequently in patients with OI, possibly related 
to the underlying metabolic disorder (26). The authors con-
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cluded that the implications of EEG fi ndings may be diff erent 
than in the general population, since changes on EEG fi nd-
ings did not appear to be correlated with the severity of ill-
ness and only one patient had a history of seizures (26).
Children with OI have normal intelligence, but they can un-
derachieve in school because of the nature of the disease 
and physical disability (27, 28).
INVOLVEMENT OF THE NERVOUS SYSTEM 
IN OSTEOGENESIS IMPERFECTA
The central nervous system is usually involved in OI due to 
softening of bone at the base of the skull, resulting in up-
wards migration of the upper cervical spine and odontoid 
process into the skull base. Upwards migration of the spine 
can cause compression of the brainstem, mechanical im-
pingement of the spinal canal with restriction of cerebrospi-
nal fl uid circulation, and impingement of the cranial nerves 
(29). Severe forms of OI are presented by debilitating skele-
tal fractures and progressive neurologic impairments may 
lead to perinatal death, while milder forms can be almost 
asymptomatic causing only modest reduction in life span. 
Osteogenesis imperfecta may directly involve neurovascu-
lar structures, leading to cavernous fi stulas of the carotid 
artery, dissection of the cervical arteries (30), and cerebral 
aneurysms (31, 32).
The brain parenchyma can be aff ected in OI, with manifes-
tations such as cerebral atrophy (33), communicating hy-
drocephalus (34), and cerebellar hypoplasia (35, 36).
CRANIOCERVICAL MANIFESTATIONS 
AND COMPLICATIONS IN OSTEOGENESIS IMPERFECTA
Craniocervical pathology is one of the most serious compli-
cations of OI, and it predominantly aff ects patients with se-
vere OI types. Cranial complications of OI include a wide 
range of abnormalities of the skull and brain parenchyma. 
The studies so far indicate that cranial base pathology can 
develop despite bisphosphonate treatment, but early initia-
tion of bisphosphonate treatment can delay development 
of craniocervical junction pathology, therefore, regular fol-
low-up of cranial base morphology is warranted, particu-
larly in patients with severe OI (37).
Skull and skull base involvement 
in osteogenesis imperfecta
Patients with OI can have triangular face shape with a prom-
inent forehead (frontal bossing) and mandibular malforma-
tion causing malocclusion of the lower and upper incisors. 
The skull is relatively large compared to the body. The fron-
tal fontanel is wider and can remain open longer than nor-
mal. Generalized impairment of membranous and endo-
chondral bone leads to excessive formation of wormian 
bones (accessory bones along the sutures) with an abnor-
mally thin or thick calvaria and premature/delayed closure 
of the fontanels and sutures. Multiple wormian bones may 
persist into adulthood (38). Flattening of the occiput can be 
present. Premature fusion of the coronal suture is followed 
by compensatory overgrowth of the sagittal suture laterally 
and lambdoid sutures caudally, resulting in the skull defor-
mity called brachycephalia. 
Neuroparenchymal involvement 
in osteogenesis imperfecta 
Cerebral hemorrhage is a potentially fatal complication of 
OI. Intracranial hemorrhages are attributed to the vertebral 
artery damage, vascular fragility, spontaneous intracranial 
hypotension, and friction between multiple bone frag-
ments of the skull (39-41). Cerebral aneurysms, carotid cav-
ernous fi stulas and cervical artery dissection have been re-
ported in OI (40, 42). There are many reports of cerebral 
hemorrhages and spinal cord injuries in children with OI, 
but only few case reports of cerebral hemorrhage in adults 
with OI and with no evident trauma (43). Defective cross-
linking of collagen, as that occurring in OI, is presumed to 
be a major contributor to cerebral artery aneurysms (44).
Generalized cerebral atrophy can develop in OI due to im-
paired outfl ow of cerebrospinal fl uid, deformation of the 
skull base, forces generated by neck muscles that hold the 
head upright, and because of intracranial venous outfl ow 
obstruction (45-47). Hydrocephalus (48) or widened basal 
cistern (49) is not uncommon in OI. There are reports of uni-
lateral cerebellar hypoplasia because of intrauterine vascu-
lar compromise due to compression of the posterior circu-
lation secondary to craniospinal anomalies (50). These facts 
emphasize the need for planning brain MRI in patients with 
more severe types of OI.
The prenatal ultrasound features of type III OI, such as 
marked ventricular dilatation, shortening of the long bones 
and deformity of the femurs, can be severe enough to make 
prenatal diagnosis possible in the second trimester of preg-
nancy. Disorders of neuronal migration are described in 
children with type II OI and can result in signifi cant neuro-
logic decline (28).
Ultrasound prenatal screening is recommended in the pres-
ence of a high familial risk of OI.
Craniocervical junction abnormalities 
in osteogenesis imperfecta
Platybasia, basilar impression and basilar invagination are 
craniocervical junction abnormalities that can occur in OI 
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because of bone softening. Basilar impression and basilar 
invagination are distinct characteristics, although many au-
thors use these two conditions as synonyms. Basilar invagi-
nation is a condition in which the odontoid process pro-
trudes upwards into the intracranial space, penetrating the 
foramen magnum (51). Basilar impression, or upwards in-
folding of the foramen magnum edge into the skull may 
lead to medullar and cerebellar displacement.
Clinical picture in patients with basilar impression develops 
slowly and progressively. Radiologic features may be pres-
ent for several years before progression of neurologic signs. 
Sillence et al. (52) found that basilar impression was radio-
logically present long before puberty. Neurologic signs of 
basilar impression can be present before symptoms and 
include nystagmus, facial spasms, nerve paresis, pyramidal 
tract signs, proprioceptive defi cits and papilledema in case 
of hydrocephalus. Neurologic symptoms develop later and 
include posterior headache (worse on movement), cough, 
sneezing, trigeminal neuralgia, balance problems, vertigo; 
weakness of arms and legs; and bladder disorders (53). Ves-
tibular dysfunction and progressive hearing impairment 
can be expected in OI, but the inexplicable fact is that some 
of adult patients with OI suff er from vertigo without any 
hearing impairment or basilar impression (23).
The diagnosis of basilar impression is radiographic. The plain 
lateral cervical spine and craniogram can show translocation 
of the upper cervical vertebral column into the posterior fos-
sa. In basilar impression and OI, there are characteristic shapes 
of the skull; one is “Tam O’Shanter” appearance of the skull 
with overhang of temporal and occipital bones resembling 
the fl oppy beret from Scotland, and the other is “Darth Vader” 
appearance of the skull, resembling the shape of helmet 
worn by Darth Vader, a Star Wars movie character (54). 
Lateral craniometry can be helpful, such as measurement 
using McRae, Chamberlain, and McGregor lines (55) (Figure 
1). McRae line is drawn from the anterior margin (basion) to 
the posterior margin (opisthion) of the foramen magnum. 
The tip of the odontoid process should normally be posi-
tioned below this line; if it is not below this line, the odon-
toid process has crossed through the foramen magnum 
into the intracranial space, and basilar invagination/impres-
sion is present. Chamberlain line is joining the back of the 
hard palate with the opisthion on lateral view of the cranio-
cervical junction. Pathologic fi nding is if the tip of the dens 
is >3 mm above this line. McGregor line is a modifi cation of 
the Chamberlain line and is used when the opisthion is not 
identifi ed on plain radiographs. It refers to a line connecting 
posterior edge of the hard palate to the most caudal point 
of the occipital curve. It is pathologic if the tip of the dens 
lies more than 4.5 mm above this line. Magnetic resonance 
imaging (MRI) is the optimal method for revealing abnor-
malities of the brain and spinal cord. Brain MRI is the meth-
od of choice for evaluating tonsillar herniation, the early 
stage of development of a syrinx, and changes in posterior 
fossa. Tonsillar herniation as a cause of brainstem compres-
sion can lead to rapid neurologic deterioration, respiratory 
arrest and death (56). Platybasia was diagnosed when the 
anterior cranial base angle was more than 2.5 SD above the 
average age-specifi c norms (57). Th e ligaments and bones 
of the craniocervical junction allow movements of the head 
and provide us with support while standing and sitting. Cra-
niocervical instability can develop in OI, where craniocervi-
cal junction anomalies have been observed in all types of 
OI, except for the perinatal lethal type (58). In some patients, 
the anomaly progressed, but in some improvement was 
seen (57). When compared with the historical group of OI 
patients with comparable severity and no exposure to 
bisphosphonates, a trend towards delayed development of 
cranial base pathology was observed (57).
The causes of craniocervical pathology in OI include a com-
bination of bone fragility and excessive ligament laxity. The 
brain compresses the cranial base, causing microfractures 
and the cervical spine migrates upwards relative to the cra-
nium (59).
Basilar impression and invagination are detected from the 
age of 2 years, while platybasia may be present from birth 
1 – OCCIPUT, 2 – CLIVUS, 3 – HARD PALATE
FIGURE 1. Cephalometric lines are important measurements in basilar 
impression/ invagination: McRae line, Chamberlain line and McGregor 
line (51). McRae line: tip of clivus (basion) to opisthion (posterior 
margin of foramen magnum) (this is essentially a measurement across 
the foramen magnum). It should be >19 mm and no part of odontoid 
should be above that line. McGregor line: posterior margin of hard 
palate to the most caudal point of occiput. No more than 4.5 mm of 
the dens should be above this line. Chamberlain line: posterior portion 
of hard palate to opisthion. No more than 3 mm of the dens should be 
above this line (original drowing by the authors). 
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(60). It has been previously suggested that platybasia predis-
poses to the development of Chiari malformation by over-
crowding of the posterior fossa and consequently to tonsillar 
herniation through the foramen magnum (61). Spontane-
ous recovery from platybasia in OI can be explained with 
further growth of the child. T he ligaments and vertebral in-
stability are likely to play a major role in the development of 
craniocervical pathology. The cranial base anomalies devel-
op despite bisphosphonate treatment, but early treatment 
can delay development of craniocervical junction pathology 
(62). Concerning natural history of basilar impression in each 
type of OI, as far as neurologic complications are yet to be 
established, until then the neurologic and radiographic 
screening for patients with OI is recommended and follow-
up for positive cases should be repeated every two to three 
years until skeletal maturity (63).
Other spinal manifestations in osteogenesis imperfecta
Abnormal bone structure, poor enchondral and periosteal 
bone formation, and absence of lamellar bone lead to corti-
cal thinning in patients with OI. Patients with OI have a wide 
range of radiologic abnormalities in the spine, including dif-
fuse osteopenia, defective cortical bone formation, sclerosis 
of vertebral endplates, and biconcave vertebral bodies. Pa-
tients with OI may be aff ected by severe kyphoscoliosis or 
marked lordosis and scoliosis. Generalized loss of height of 
the thoracic vertebrae (platyspondyly) is another character-
istic feature of the disease. 
The prevalence of kyphoscoliosis in patients with OI ranges 
from 39% to 80%, depending on the study (64). Scoliosis is 
rarely observed in patients below 6 years of age and can 
progress rapidly after it has been diagnosed (65). The etiology 
of scoliosis in OI is still controversial, but vertebral fractures are 
thought to be the leading cause of scoliosis due to severe 
fragility of the vertebral growth plates and progression with 
growth (66). The poorer bone quality leads to more severe 
scoliosis (67). Untreated scoliosis progresses in children with 
OI, even into adulthood (68). Ishikawa et al. found that bicon-
cave vertebrae were common in patients with OI and the 
presence of six or more biconcave vertebrae before puberty 
suggested that severe scoliosis would develop (66). Patients 
with type III OI with bisphosphonate treatment before age 6 
had slower curve progression, whereas patients with type I or 
IV OI had no eff ect of therapy (69). 
LUMBOSACRAL ABNORMALITIES 
IN OSTEOGENESIS IMPERFECTA
Spondylolysis and spondylolisthesis have been found in pa-
tients with OI, mainly at the L5/S1 level, with the incidence 
of 5% to 10%. (69). The clinical relevance and data on surgi-
cal indications of spondylolysis and spondylolisthesis in pa-
tients with OI are still not clear, and can be evaluated from 
few case reports.
SLEEP IN OSTEOGENESIS IMPERFECTA
For more than 100 years now, sleep has been studied and 
used as therapy for many illnesses. Today, we are aware of 
circadiurnal rhythms of many biologic processes and the 
awareness of the importance of balanced quality and quan-
tity of sleep is growing. 
Sleep in rare genetic disorders is being studied, especially in 
those diseases that aff ect craniocervical structures such as 
specifi c syndromes, e.g., Apert, Crouzon, Pfeiff er syndromes, 
or respiratory chest wall such as skeletal dysplasias, or spinal 
deformities and morbid obesity such as Prader Willi syn-
drome. The patients with OI have abnormal chest wall archi-
tecture and abnormal lung collagen and they tend to de-
velop chest wall and spinal deformities due to scoliosis and 
fractures. Only few studies looked at the eff ects of abnormal 
lung collagen and helped explain why patients with mild OI 
have a higher tendency to asthma and pneumonia (64). 
The latest data reveal the prevalence of obstructive sleep 
apnea (OSA) in the general population (≥5 events/h in 
adults and ≥1 events/h in children), with the apnea-hypop-
nea index (AHI) of 9% to 38% (70).
People with OI seem to have a very high frequency of sleep 
related breathing problems, especially in cases where there 
is compromised growth and evident craniofacial and dental 
dysmorphic features, but there is still no information on the 
incidence of specifi c sleep disorders such as sleep apnea, 
sleep fragmentation, or excessive daily sleepiness in chil-
dren or adults with OI. All data can only be traced from case 
reports.
In cases of seriously compromised structures of craniocervi-
cal junction in patients with OI, one could expect signifi cant 
central sleep apnea, but published case reports on central 
sleep apnea mainly involve Arnold-Chiari malformation in 
OI and central sleep apnea as its clinical manifestation (71). 
The pathophysiologic mechanisms of such sleep apnea are 
a blunted bulbar chemical drive (if hypercapnia is present) 
or an increased bulbar chemical drive that destabilizes the 
breathing pattern during sleep (in normocapnic and hypo-
capnic patients). Other anomalies such as bone malforma-
tions (platybasia) or syryngobulbomyelia can be involved. 
Other respiratory manifestations can be observed such as 
obstructive sleep apnea syndrome (OSAS), diaphragmatic 
or vocal cord paralysis. One case report showed signifi cant 
obstructive sleep apnea due to unexpected laryngomalacia 
in an adult with OI (72).
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Overnight polysomnography is a noninvasive diagnostic 
method, but there is a strong need to minimize the possibil-
ity of injuries during the night in another environment and 
to ensure maximal relaxation of the child or adult with OI. 
We recommend the child with OI in the sleep laboratory to 
sleep in the position he tends to have at home. Overnight 
polysomnography in patients with OI should include video 
infrared camera, microphone for vocalizations, 6-channel 
EEG, left and right electrooculography, chin and tibial elec-
tromyography (surface electrodes), nasal pressure transduc-
er and nasal thermistor, thoracic/abdominal plethysmogra-
phy (strain gauge), electrocardiography (2nd lead), sensors 
for pulse, and peripheral blood oxygen saturation (Figure 2). 
We recommend CO2 end tidal measurement in children 
where hypercapnia is suspected. Patients should fi ll-in a 
short questionnaire about sleep and sleeping issues. Health 
professionals should off er overnight polysomnography to 
the patient with OI as a screening method, especially if 
there are chronic pulmonary issues such as asthma or fre-
quent respiratory infections and craniocervical/neurologic 
abnormalities. Parents are not aware of sleep breathing is-
sues in children with chronic and rare diseases such as OI 
and they frequently underreport sleep apnea, awakenings 
and sleep fragmentation in their children. There are still no 
clinical studies analyzing sleep issues in children/adults 
with OI and there is still no recognizable sleep phenotype in 
OI. The average apnea/hypopnea scores have not yet been 
established in children and adults with OI. There are no 
studies analyzing the possible daily sleepiness in patients 
with OI. Excessive daily sleepiness is an important risk factor 
for tendency to traumatic accidents and it can be fatal in OI. 
There are some insights in sleep polysomnographic param-
eters in neuromuscular diseases where the authors had one 
or few patients with OI within the cohort of patients with 
diff erent neuromuscular diseases (73). 
Since there are seventeen genetic types of OI, it is yet to be 
established the phenotype-genotype correlation not only 
for skeletal manifestation, but also for other issues such as 
respiratory manifestations and sleep disturbances. OSAS 
should be considered as a multifactorial disease with the 
genetic basis and risk factors such as obesity, central control 
of ventilation, and craniofacial morphology (74). So far, 
FIGURE 2. Hypnogram and one epoch of the overnight polysomnography (30 seconds) of a 6-year-old boy with osteogenesis 
imperfecta type I. The patient also has allergic asthma, he sweats a lot during the night, and sleeps restlessly with frequent 
turnovers. Overnight polysomnography was performed in our sleep laboratory. His apnea-hypopnea score was 0, but he had 
prolonged REM latency (180 minutes) and lower average oxygen saturation in sleep (95%). The recorded parameters from the 
top to the bottom are: electroencephalogram (EEG), chin electromyogram (CHIN), leg electromyogram (LEG), snore detector 
(SNORE), electrocardiogram (ECG), respiratory fl ow sensors (PRESSURE P, PRESSURE), chest and abdominal plethysmography 
(CHEST, ABDOMEN), peripheral oxygen saturation (spO2%) and hypnogram (H) with sleep stages at the bottom of 
polysomnographic fi nding.
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many genes are involved in OSAS, from the genes that in-
duce migration of specifi c cellular groups to the genes lead-
ing to structural organizations (75). The association of these 
genes with sleep disorder in patients with OI has not yet 
been studied.
PERSPECTIVES IN OSTEOGENESIS IMPERFECTA
The essential pathophysiologic feature of OI is an increased 
bone turnover. Therefore, the most important advance in 
medical treatment has been the introduction of bisphos-
phonate therapy for patients with a moderate to severe 
form of OI (76). Bisphosphonates are eff ective in reducing 
osteoclast-mediated bone resorption. Intravenous pami-
dronate therapy administered in repeated courses over sev-
eral years reduces the incidence of bone fractures and in-
creases bone density, vertebral body height, and cortical 
bone thickness (77). Since patients with type VI OI are 
known to have poor response to such a bisphosphonate 
treatment, the experiences with the monoclonal RANKL an-
tibody denosumab are promising (78, 79). In patients with 
severe basilar invagination, neurosurgery may be necessary 
with inevitable mobilization leading to diff use atrophy of 
the muscles and ankylosis of the joints, and therefore should 
be avoided. There are no approved physiotherapy treat-
ment approaches available in children with OI yet, but an 
intensive functional therapeutic approach including home 
based training approach leads to an increase of mobility in 
children with OI, which is followed by an increase of bone 
mineral content and bone mineral density (80).
In conclusion, neurodevelopmental issues, neurologic man-
ifestations and sleep disorders are valuable prognostic fac-
tors and highly important features within the phenotypic 
complexity of OI. The measures of prevention in OI stress 
the need for regular multidisciplinary monitoring of these 
issues, as well as of other complications from an early age, 
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S A Ž E T A K
Neurološke manifestacije i osobitosti spavanja 
u osteogenesis imperfecta
Romana Gjergja Juraški, Mirjana Turkalj, Ivan Mikula, Dragan Primorac
Osteogenesis imperfecta (OI) je rijedak genetički poremećaj koji dovodi do krhkosti kostiju, prijeloma i deformiteta. Glavni patofi zio-
loški učinak OI je smanjenje u kvaliteti ili kvantiteti kolagena tip I te su stoga zahvaćene strukture koje normalno sadrže kolagen tip 
I. U 80% slučajeva postoje promjene u genima COL1A1 i COL1A2. Naš cilj je bio pretražiti relevantne podatke o neurorazvoju, spava-
nju i neurološkim komplikacijama u OI. Živčani sustav je zahvaćen u OI zbog omekšavanja kosti na bazi lubanje, što rezultira migra-
cijom gornjeg dijela cervikalne kralježnice i odontoidnog procesusa. Bolest može izravno zahvatiti neurovaskularne strukture pa 
nastaju kavernozne fi stule, disekcije ili aneurizme. Moždani parenhim je zahvaćen u OI, s kliničkim entitetima kao što su cerebralna 
atrofi ja, komunicirajući hidrocefalus i cerebelarna hipoplazija. Bazilarna impresija/invaginacija su ozbiljne abnormalnosti kranio-
cervikalne veze i mogu biti životno ugrožavajuće. Zasad postoji vrlo malo saznanja o obrascima spavanja u OI. Neurološke kompli-
kacije i poremećaji spavanja su korisni prognostički čimbenici i izrazito važne manifestacije unutar složenog fenotipa u OI. Mjere 
prevencije u OI ukazuju na potrebu redovitog praćenja ove problematike od rane dobi i edukacije bolesnika s OI i njihovih obitelji.
Ključne riječi: osteogenesis imperfecta, živčani sustav, neurorazvoj, apneja u spavanju
